BPC-157 and TB-500: a research overview

BPC-157

BPC-157 is a synthetic 15-residue peptide corresponding to a partial sequence of a protein found in gastric juice. Its stability under acidic conditions is part of why it became a common laboratory reference standard.

The published work is preclinical. In cell-culture and rodent models it appears in studies of angiogenesis, fibroblast migration, tendon-to-bone healing kinetics, and gastrointestinal mucosal repair, and is often discussed alongside growth-factor and nitric-oxide signalling in those experimental contexts.

The scope of that literature is worth stating directly: animal-model and in-vitro findings do not establish human effects, and BPC-157 is not an approved therapeutic in Canada or elsewhere.

TB-500

TB-500 is a synthetic peptide corresponding to a biologically active region of Thymosin Beta-4, a naturally occurring actin-sequestering protein.

In preclinical research the corresponding region is studied for its role in actin regulation and cell migration, in in-vitro and animal-model contexts. As with BPC-157, this is a research literature rather than a clinical one.

The two are frequently studied side by side, which is why they are often discussed together — not because that comparison implies anything about use.

Why purity and identity matter to the work

Results are only as reliable as the material behind them. A mislabelled or contaminated batch does not produce a null result; it produces a confounded one, and often an unreproducible one, which is worse because it is harder to notice.

Two separate questions are worth answering before a batch goes into an experiment. How pure is it — the HPLC number, ideally with the chromatogram. And is it the right molecule — which is what a mass-spec identity run establishes, and which HPLC purity alone does not.

The published Canada Peptide Testing reports measure RP-HPLC-UV area purity and content. They do not include mass-spectrometry identity, endotoxin, water content or a related-substances breakdown. These results do not establish clinical safety or regulatory approval.

Verifying the batch in front of you

Match the batch number on the certificate to the batch number on the vial. If they do not correspond exactly, the certificate is about different material.

Look at the chromatogram rather than only the percentage — one clearly dominant peak, without a cluster of large neighbours.

Read measured content separately from area purity; water content is not reported on the published CPT set.

Match the compound, vial size and printed lot to the report before relying on it. An assigned reference is not automatically the batch code on a vial. If they differ, email purenorthpeptides@proton.me with the vial details and report number to confirm the connection. Do not extend a report to another size or lot.

Frequently asked

Is the BPC-157 and TB-500 research clinical?

No. The body of work is preclinical — in-vitro and animal-model studies. Preclinical findings do not establish effects in humans.

Are they approved for human use in Canada?

No. Both are supplied as research-use-only laboratory reference standards, not as products approved for human use.

What should I check before using a batch?

A matching sample and size, the original report, the HPLC area-purity figure and the measured content result. If independent identity confirmation matters to your work, arrange a mass-spec run — our certificates do not include one.

Are your certificates independent?

Pure North commissioned Canada Peptide Testing, as a paying client, and publishes 13 independent reports at /lab-results/. Each report covers only its named sample, vial size and lot or assigned reference. Manufacturer QC documents may be available on request for other peptide lots; they are not independent reports. Selank, Semax and Tirzepatide COAs are temporarily unavailable. Bacteriostatic water has no COA.

Referenced in our catalog

Related library entries